CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 121 enrolled / 121 target
Drug / intervention
Oxytocin nasal spray or placebodrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05968651
NCT05968651Phase 2CompletedHigh Momentum (3.3/mo)Completion was 21mo ago

Social Safety Learning in the Brain Oxytocin System

University of Washington·interventional·Posted Aug 1, 2023·Updated Jun 11, 2026

In Brief

A Phase 2 clinical trial evaluating Oxytocin nasal spray or placebo for Social Phobia. Completed, enrolled 121 participants across 1 site.

Signals

Enrolling ahead of pace

Detailed Summary

The investigators are conducting this research study to examine whether oxytocin enhances social safety learning (learning safety through the experience of another individual) in people with social anxiety disorder (SAD) compared to healthy volunteers. Oxytocin is a hormone that can also act as a chemical messenger in the brain. Oxytocin plays a role in a number of functions, including responding to fear and social interactions. In this study, the investigators would like to compare the effects of oxytocin and placebo nasal sprays in adults with SAD and healthy adults. This research study will compare an oxytocin nasal spray to a placebo nasal spray. About 120 people will take part in this research study, all at the University of Washington (UW).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSocial Phobia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202420252026
First PostedAug 1, 2023
Enrollment StartJun 26, 2023
Primary CompletionSep 30, 2024
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 2.9 years ago

Arms & Interventions

Clinicalexperimental

This group consists of individuals with at least moderate symptoms of social anxiety disorder. This group will receive either an oxytocin or placebo administration (blind randomization).

Drug: Oxytocin nasal spray or placebo
Controlsplacebo_comparator

This group consists of a healthy sample of individuals (no lifetime diagnoses of mania or psychotic disorders). This group will receive either an oxytocin or placebo administration (blind randomization).

Drug: Oxytocin nasal spray or placebo

Interventions

Oxytocin nasal spray or placebodrug

Single acute administration of 24 international units (IU) oxytocin or matching placebo